Evidence map›Paper›PMID 41852326›Full record

ArticleHaematologica2026

Phase I study of the safety and pharmacokinetics of CSL889 (hemopexin) in adults with sickle cell anemia.

Bart J Biemond, Rachel Kesse-Adu, Ezanul Wahab, Roberta C G Azbell, Alexander A Boucher, Perla Eleftheriou, Laura M De Castro, Shayla Bergmann, William D Hedrich, Francine R Wilson and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Bart J BiemondDepartment of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam.
Rachel Kesse-AduDepartment of Hematology, Guy's and St Thomas' Hospit al, London.
Ezanul WahabMAC Clinical Research, Manchester.
Roberta C G AzbellDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, The OSU Wexner Medical Center, Columbus, OH.
Alexander A BoucherDepartment of Medicine, University of Minnesota, Minneapolis, MN.
Perla EleftheriouUniversity College London Hospital, London.
Laura M De CastroDepartment of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA.
Shayla BergmannMedical University of South Carolina, Charleston, SC.
William D HedrichCSL Behring, King of Prussia, PA.
Francine R WilsonCSL Behring, King of Prussia, PA.
Kerstin JungCSL Innovation GmbH, Marburg.
Michael AracoCSL Innovation, Victoria.
Rongrong WangCSL Behring, King of Prussia, PA.
Paul M ShoreCSL Behring, King of Prussia, PA. Paul.Shore@cslbehring.com.
Gregory J KatoCSL Behring, King of Prussia, PA.
Victor R GordeukDepartment of Medicine, University of Illinois at Chicago, Chicago, IL.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41852326
PMCPMC13530956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.